Trial Profile
Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 In Patients With Ischemic Cardiomyopathy and Angina.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary) ; Omecamtiv mecarbil (Primary)
- Indications Angina pectoris; Cardiomyopathies; Heart failure
- Focus Therapeutic Use
- Sponsors Cytokinetics
- 15 Sep 2009 Results were presented at the 2009 Heart Failure Society of America Annual Meeting in Boston, Massachusetts, according to a Cytokinetics media release.
- 31 Aug 2009 Results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
- 31 Aug 2009 Results were presented at the European Society of Cardiology Congress 2009, according to a Cytokinetics media release.